Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MVA85A · 1 trial · 1 indication
To evaluate the safety profile of multiple doses of AERAS-402 alone, compared to one and two doses of AERAS-402 followed by MVA85A in healthy, BCG vaccinated adults, measured by number and severity of local and systemic adverse events
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Two doses of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection) |
| Group B | EXPERIMENTAL | One dose of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection) |
| Group C | EXPERIMENTAL | Three doses of AERAS-402 (1x10\^11 vp intramuscular injection) |
| Name | Type | Description |
|---|---|---|
| AERAS-402 | BIOLOGICAL | Intramuscular needle injection 1x10\^11 vp |
| MVA85A | BIOLOGICAL | Intradermal needle injection 1x10\^8 pfu |
Inclusion Criteria: Subjects must meet all of the following criteria to enter the trial: * Healthy adult aged 18-55 years * Resident in or near Oxford (for CCVTM) or Birmingham (for WTCRF; and able to travel to Oxford for vaccinations) for the duration of the trial period * No relevant findings in...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Viatris, Inc. | VTRS | 1 | PHASE3 | Bedaquiline |
| Johnson & Johnson | JNJ | 1 | PHASE2 | Bedaquiline, Background Regimen |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT164a1, BNT164b1 |